Amgen stock: Dazodalibep meets both Phase 3 Sjogren's endpoints
Amgen stock: Dazodalibep meets both Phase 3 Sjogren's endpoints ad-hoc-news.de
Covered in this story
What has happened since
- Amgen is up 0.0% since this was published.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Amgen
- Argus Research: at $469 · target $515 by Nov 2027 · Buy via Investing.com India
- Freedom Broker: at $460 · target $470 by Nov 2027 · Hold via Investing.com
- Cantor Fitzgerald: at $478 · target $465 by Nov 2027 · Neutral via MarketBeat
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Amgen →Dalsna Finance is currently tracking 48 stories mentioning Amgen, the earliest published 28 Apr 2017.
Summary aggregated from ad-hoc-news.de's public RSS feed. The full reporting belongs to ad-hoc-news.de — please read it on their site.